Your browser doesn't support javascript.
loading
Diagnostic and prognostic biomarkers for progressive fibrosing interstitial lung disease.
Watase, Mayuko; Mochimaru, Takao; Kawase, Honomi; Shinohara, Hiroyuki; Sagawa, Shinobu; Ikeda, Toshiki; Yagi, Shota; Yamamura, Hiroyuki; Matsuyama, Emiko; Kaji, Masanori; Kurihara, Momoko; Sato, Midori; Horiuchi, Kohei; Watanabe, Risa; Nukaga, Shigenari; Irisa, Kaoru; Satomi, Ryosuke; Oyamada, Yoshitaka.
Afiliação
  • Watase M; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Mochimaru T; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Kawase H; Department of Allergy, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Shinohara H; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Sagawa S; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Ikeda T; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Yagi S; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Yamamura H; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Matsuyama E; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Kaji M; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Kurihara M; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Sato M; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Horiuchi K; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Watanabe R; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Nukaga S; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Irisa K; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Satomi R; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • Oyamada Y; Department of Respiratory Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
PLoS One ; 18(3): e0283288, 2023.
Article em En | MEDLINE | ID: mdl-36930615
ABSTRACT
No biomarkers have been identified in bronchoalveolar lavage fluid (BALF) for predicting fibrosis progression or prognosis in progressive fibrosing interstitial lung disease (PF-ILD). We investigated BALF biomarkers for PF-ILD diagnosis and prognosis assessment. Overall, 120 patients with interstitial pneumonia who could be diagnosed with PF-ILD or non PF-ILD were enrolled in this retrospective study. PF-ILD was diagnosed according to Cottin's definition. All patients underwent bronchoscopy and BALF collection. We evaluated blood and BALF parameters, high-resolution computed tomography (HRCT) patterns, and spirometry data to identify factors influencing PF-ILD diagnosis and prognosis. On univariate logistic analysis, age, sex, the BALF white blood cell fraction (neutrophil, lymphocyte, eosinophil, and neutrophil-to-lymphocyte ratio), BALF flow cytometric analysis (CD8), and an idiopathic pulmonary fibrosis/usual interstitial pneumonia pattern on HRCT were correlated with PF-ILD diagnosis. Multivariate logistic regression analysis revealed that sex (male), age (cut-off 62 years, area under the curve [AUC] 0.67; sensitivity 0.80; specificity 0.47), white blood cell fraction in BALF (NLR, neutrophil, and lymphocyte), and CD8 in BALF (cut-off 34.2; AUC 0.66; sensitivity, 0.74; specificity, 0.62) were independent diagnostic predictors for PF-ILD. In BALF, the NLR (cut-off 8.70, AUC 0.62; sensitivity 0.62; specificity 0.70), neutrophil count (cut-off 3.0, AUC 0.59; sensitivity 0.57; specificity 0.63), and lymphocyte count (cut-off 42.0, AUC 0.63; sensitivity 0.77; specificity 0.53) were independent diagnostic predictors. In PF-ILD patients (n = 77), lactate dehydrogenase (cut-off 275, AUC 0.69; sensitivity 0.57; specificity 0.78), Krebs von den Lungen-6 (cut-off 1,140, AUC 0.74; sensitivity 0.71; specificity 0.76), baseline forced vital capacity (FVC) (cut-off 1.75 L, AUC 0.71; sensitivity, 0.93; specificity, 0.46), and BALF neutrophil ratio (cut-off 6.0, AUC 0.72; sensitivity 0.79; specificity 0.80) correlated with death within 3 years. The BALF cellular ratio, particularly the neutrophil ratio, correlated with the diagnosis and prognosis of PF-ILD. These findings may be useful in the management of patients with interstitial pneumonia.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Pulmonares Intersticiais / Fibrose Pulmonar Idiopática Idioma: En Ano de publicação: 2023 Tipo de documento: Article